We describe the utilization of UTE-3D Cones to create T2* maps of iron deposition in the hippocampus of an Alzheimer’s dementia subject, but not in a corticobasal degeneration subject. These results are consistent with histopathological studies involving post-mortem human brain tissue. UTE-3D Cones could be a promising imaging protocol for AD diagnostic imaging.
INTRODUCTION
Alzheimer’s disease (AD) – a progressive, neurodegenerative, and incurable disorder – is the most common form of dementia diagnosed in people over age 65. It looms as a major threat to public health in the first half of the 21st Century. Dementia doubles in frequency every five years after age 60, afflicting 1% of those aged 60-64 but rising to 30-40% of those 85 years and older1. Growing evidence demonstrates that oxidative stress is an important factor contributing to the initiation and progression of AD2-6. Iron is an essential trace mineral required for proper neuronal function but if iron becomes free in the neuron or surrounding environment, its redox transitions between Fe(II) and Fe(III) generate radicals. Additionally, Fe(III) binds to hyper-phosphorylated tau (HP-tau) and induces its aggregation into tangles. HP-tau aggregation is reversible in vitro by chemically reducing Fe(III) to Fe(II), indicating the possibility that similar treatments may be possible to eliminate tau tangles in vivo7. Our own preliminary immunohistochemistry studies have shown that in the medial temporal lobe, iron co-localizes with amyloid beta (Aβ) plaques, and/or with HP-tau, depending on the anatomical region, severity of AD diagnosis, and age of the patient at death. These findings are particularly important since iron can be visualized with Magnetic Resonance Imaging (MRI). Indeed, our preliminary T2* imaging studies with post-mortem human brain specimens and concomitant histopathological analysis demonstrate that iron co-localization with AD pathological proteins is dependent on anatomy, disease severity, and age. Therefore, iron imaging has noteworthy promise as a potential imaging biomarker for AD.1. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta psychiatr scand. 1987;76:465-79.
2. Zhao Y, Zhao B. Oxidative stress and the pathogenesis of Alzheimer's disease. Oxid Med Cell Longev. 2013;2013:316523. Epub 2013/08/29. doi: 10.1155/2013/316523. PubMed PMID: 23983897; PMCID: 3745981.
3. Mondragon-Rodriguez S, Perry G, Zhu X, Moreira PI, Acevedo-Aquino MC, Williams S. Phosphorylation of tau protein as the link between oxidative stress, mitochondrial dysfunction, and connectivity failure: implications for Alzheimer's disease. Oxidative medicine and cellular longevity. 2013;2013:940603. Epub 2013/08/13. doi: 10.1155/2013/940603. PubMed PMID: 23936615; PMCID: 3723250.
4. Friedman A, Arosio P, Finazzi D, Koziorowski D, Galazka-Friedman J. Ferritin as an important player in neurodegeneration. Parkinsonism Relat Disord. 2011;17(6):423-30. Epub 2011/05/10. doi: 10.1016/j.parkreldis.2011.03.016. PubMed PMID: 21550835.
5. Jomova K, Vondrakova D, Lawson M, Valko M. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem. 2010;345(1-2):91-104. Epub 2010/08/24. doi: 10.1007/s11010-010-0563-x. PubMed PMID: 20730621.
6. Arosio P, Levi S. Ferritin, iron homeostasis, and oxidative damage. Free Radic Biol Med. 2002;33(4):457-63. Epub 2002/08/06. PubMed PMID: 12160928.
7. Yamamoto A, Shin RW, Hasegawa K, Naiki H, Sato H, Yoshimasu F, Kitamoto T. Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease. J Neurochem. 2002;82(5):1137-47. Epub 2002/10/03. PubMed PMID: 12358761.